

<b>File reference</b>	W17FOI313
<b>Key words</b>	Prostate Cancer and Gastrointestinal Stromal Tumours – Drug treatment
<b>Date of release</b>	10/08/2017
<b>Attachments</b>	Yes –L3

## Freedom of Information Act Disclosure log - Reply Extract

### You asked

- 1. How many unique patients with Advanced Prostate Cancer have been treated in the past 12 months?**

Advanced prostate cancer is cancer that has spread outside the prostate to other parts of the body such as the bones and commonly known as stage 4. The Trust does not currently separately record Stage 4 advanced prostate cancer within its electronic patient records. The information would be recorded in each patient's clinical record, however the Trust could not locate, extract and collate the information requested within the appropriate limit as specified in section 12(1) of the Act – Request exceeds the appropriate limit.

- 1a. How many patients with Advanced Prostate Cancer have received ;**

<b>Drug</b>	<b>Number of advanced prostate cancer patients receiving treatment between 1/6/16 to 31/5/17</b>
Abiraterone (Zytiga)	66
Cabazitaxel (Jevtana)	8
Docetaxel (Taxotere)	38
Enzalutamide (Xtandi)	37
Radium-223 (Xofigo)	59 (This figure includes non PHNT patients)
Bicalutamide (Casodex)	(64* patients in total) We cannot distinguish advanced prostate cancer for this medicine

- 2. How many unique patients with Gastrointestinal Stromal Tumours have been treated in the past 12 months?**

There were 19 Patients with GIST diagnoses in the last 12 months.

**2a. How many patients with Gastrointestinal Stromal Tumours (GIST) have received;**

<b>Drug</b>	<b>Number of GIST patients receiving treatment between 1/6/16 to 31/5/17</b>
Dasatinib (Sprycel)	0
Imatininb (Glivec)	11
Nilotinib (Tasigna)	0
Pazopanib (Votrient)	0
Regorafenib (Stivarga)	Five or fewer
Sorafenib (Nexavar)	0
Sunitinib (Sutent)	0

**Legal notes**

Plymouth Hospitals NHS Trust is confirming in accordance with section 1 (a) of the Act that it holds the information requested and is supplying it in accordance with section 1(b) unless otherwise specified.

Please find the answers to your questions noting that we have redacted the data set where numbers are five or fewer. This avoids a breach of the first two Data Protection Act principles. This is in accordance with section 40.-(2)(a) and (b) by virtue of section 40.-(3)(a)(i), the personal information exemption as described in the Freedom of Information Act. A detailed rationale is provided in the attached document L3.